ES
JSPRW icon

Equitec Specialists’s Japer Therapeutics Warrants JSPRW Stock Holding History

Equitec Specialists’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,536
Closed -$11K – 48
2021
Q1 		$11K Sell
13,536
-15,665
-54% -$22.9K ﹤0.01% 204
2020
Q4 		$42K Buy
+29,201
New +$36.6K ﹤0.01% 172

Other funds holding JSPRW

OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return

Equitec Specialists's JSPRW Position: Q2 2021 in Review

Equitec Specialists sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2021, closing a stake of 13,536 shares — an estimated $11K sold.

Equitec Specialists first reported a position in JSPRW in Q4 2020 and held it in 2 quarters. The position peaked at $42K in Q4 2020. 21 funds tracked by Wall St. Rank hold JSPRW as of Q2 2021.

  • Equitec Specialists reported no remaining Japer Therapeutics Warrants position as of Q2 2021 after selling out during the quarter.
  • Equitec Specialists sold 13,536 Japer Therapeutics Warrants shares in Q2 2021, an estimated $11K.
  • Equitec Specialists first reported a position in Japer Therapeutics Warrants in Q4 2020 and held it in 2 quarters.
  • Equitec Specialists's Japer Therapeutics Warrants position peaked at $42K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2021.

Based on Equitec Specialists's 13F filing for Q2 2021, filed 20 Jul 2021.